Aripiprazole Online

How and where to order Aripiprazole (Abilify) tablets online on Centre jeunesse du Bas-Saint-Laurent:

Shop:	DFH PHARMACY
Stores:	PHARMA DOCTOR
Prices:	from $0.51 per pill
Discount:	10% coupon: DFHDCC
Forms:	5 mg, 10 mg, 15 mg, 20 mg, 30 mg tablets or capsules
Quantity:	30-360 pills
Type:	Aripiprazole brand, Abilify generic
Payment:	Visa, MasterCard, AmEx, E-Check (ACH), Bitcoin
Delivery:	Regular and express mail service
Shipping:	Worldwide, including USA, UK, Europe, Canada, Australia

Aripiprazole (trade names include Abilify, Aripiprex, Aristada, Abilify Discmelt, Arip-MT, Arpizol, Abilify Maintena, Asprito, Azymol, Ilimit, Irazem, Zolerip) is an atypical antipsychotic. This medication is indicated for the treatment of schizophrenia and bipolar disorder (manic-depressive illness). Aripiprazole is also used in adjunctive treatment of depression, major depressive disorder, schizoaffective disorder, irritability associated with autism or autistic disorder, tic disorders, Tourette's disorder, borderline personality disorder, post traumatic stress disorder, obsessive-compulsive disorder, agitated state, agitation associated with schizophrenia or bipolar mania, special considerations in treating pediatric schizophrenia, bipolar 1 disorder, irritability associated with autistic disorder, and other mental conditions. Aripiprazole is also in research studies for counter-therapeutic treatment for methamphetamine dependency. It works by affecting certain substances in the brain.

Abilify (Aripiprazole)

Related medications:

Atomoxetine (Strattera)

Buspar (Buspirone)

Cariprazine

Chlorpromazine (Thorazine)

Clomipramine (Anafranil)

Clozapine (Clozaril)

Divalproex (Depakote)

Iloperidone (Fanapt)

Lamotrigine (Lamictal)

Lithium Carbonate (Lithobid)

Loxapine (Loxitane)

Mosapramine

Paliperidone (Invega)

Piracetam (Nootropil)

Prochlorperazine (Compazine)

Prothipendyl (Dominal)

Quetiapine (Seroquel)

Risperidone (Risperdal)

Thioridazine (Mellaril)

Trazodone (Desyrel)

Ziprasidone (Geodon)

Zotepine (Nipolept)

Pharmacological and medical categories:

Add-on treatment medications

Antidepressants

Atypical antipsychotics

Neuroleptic agents

ATC codes:

N - Nervous system

N05 - Psycholeptics

N05A - Antipsychotics

N05AX - Other antipsychotics

N05AX12 - Aripiprazole

ICD-10 codes:

Schizophrenia, schizotypal and delusional disorders - F20-F29

Schizoaffective disorders - F25

Bipolar disorder, single manic episode - F30

Bipolar disorder (bipolar affective disorder) - F31

Major depressive disorder, single episode - F32

Major depressive disorder, recurrent - F33

Obsessive-compulsive disorder - F42

Reaction to severe stress, and adjustment disorders - F43

Post-traumatic stress disorder (PTSD) - F43.1

Specific personality disorders - F60

Borderline personality disorder - F60.3

Pervasive developmental disorders - F84

Tic disorder - F95

Tourette's disorder - F95.2

Autistic disorder - F84.0

Symptoms and signs involving emotional state - R45

Restlessness and agitation - R45.1

Irritability and anger - R45.4

Indications and usage:

Abilify (Aripiprazole) is an atypical antipsychotic. The oral formulations are indicated for:

Schizophrenia.

Acute treatment of manic and mixed episodes associated with bipolar I.

Adjunctive treatment of major depressive disorder.

Irritability associated with autistic disorder.

Treatment of Tourette's disorder.

The injection is indicated for agitation associated with schizophrenia or bipolar mania.

Dosage and administration:

Oral formulations of aripiprazole: administer once daily without regard to meals.

IM injection: wait at least 2 hours between doses. Maximum daily dose 30 mg.

Known CYP2D6 poor metabolizers: half of the usual dose.

Dosage forms and strengths:

Oral formulations of Aripiprazole (Abilify): administer once daily without regard to meals.

IM injection: wait at least 2 hours between doses. Maximum daily dose 30 mg.

Known CYP2D6 poor metabolizers: half of the usual dose.

Overdosage:

No specific information is available on the treatment of overdose with Abilify (Aripiprazole). An electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers.

Charcoal: In the event of an overdose of Abilify, an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15mgoral dose of Abilify, decreased the mean AUCand Cmaxof aripiprazole by 50%.

Hemodialysis: Although there is no information on the effect of hemodialysis in treating an overdose with this drug, hemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.

Contraindications:

Known hypersensitivity to Aripiprazole (Abilify).

Warnings and precautions:

Cerebrovascular adverse reactions in elderly patients with dementia-related psychosis: increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack, including fatalities).

Neuroleptic malignant syndrome: manage with immediate discontinuation and close monitoring.

Tardive dyskinesia: discontinue if clinically appropriate.

Metabolic changes: atypical antipsychotic drugs have been associatedwith metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain.

Hyperglycemia/diabetes mellitus: monitor glucose regularly inpatients with and at risk for diabetes.

Dyslipidemia: undesirable alterations in lipid levels have beenobserved in patients treated with atypical antipsychotics.

Weight gain: weight gain has been observed with atypical antipsychotic use. Monitor weight.

Pathological gambling and other compulsive behaviors: consider dose reduction or discontinuation.

Orthostatic hypotension: monitor heart rate and blood pressure and warnpatients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope.

Leukopenia, neutropenia, and agranulocytosis: have been reported withantipsychotics including Abilify. Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy anddiscontinuation of Aripiprazole should be considered at the first sign of aclinically significant decline in WBC in the absence of other causative factors.

Seizures/convulsions: use cautiously in patients with a history of seizuresor with conditions that lower the seizure threshold.

Potential for cognitive and motor impairment: use caution whenoperating machinery.

Suicide: the possibility of a suicide attempt is inherent in schizophrenia and bipolar disorder. Closely supervise high-risk patients.

Side effects, adverse reactions:

Commonly observed adverse reactions (incidence >= 5% and at least twice that for placebo) of aripiprazole were:

Adult patients with schizophrenia: akathisia.

Pediatric patients (13 to 17 years) with schizophrenia: extrapyramidal disorder, somnolence, and tremor.

Adult patients (monotherapy) with bipolar mania: akathisia, sedation, restlessness, tremor, and extrapyramidal disorder.

Adult patients (adjunctive therapy with lithium or valproate) with bipolar mania: akathisia, insomnia, and extrapyramidal disorder.

Pediatric patients (10 to 17 years) with bipolar mania: somnolence,extrapyramidal disorder, fatigue, nausea, akathisia, blurred vision, salivary hypersecretion, and dizziness.

Adult patients with major depressive disorder (adjunctive treatment to antidepressant therapy): akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision.

Pediatric patients (6 to 17 years) with autistic disorder: sedation, fatigue,vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy.

Pediatric patients (6 to 18 years) with Tourette's disorder: sedation, somnolence, nausea, headache, nasopharyngitis, fatigue, increased appetite.

Adult patients with agitation associated with schizophrenia or bipolar mania: nausea.

To report suspected adverse reactions, contact Otsuka Pharmaceutical, Bristol-Myers Squibb companies or your local FDA.

Drug interactions:

Known CYP2D6 poor metabolizers: administer half of usual dose.

Known CYP2D6 poor metabolizers and strong CYP3A4 inhibitors: administer a quarter of usual dose.

Strong CYP2D6 or CYP3A4 inhibitors: administer half of usual dose.

Strong CYP2D6 and CYP3A4 inhibitors: administer a quarter of usual dose.

Strong CYP3A4 inducers: double usual dose over 1 to 2 weeks.

Use in specific populations:

Pregnancy: Aripiprazole (Abilify) may cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure.

Pregnancy categories:

B3 - Australia

C - United States (Risk cannot be ruled out)

Salts and other forms:

Aripiprazole Base

Aripiprazole Fumarate

Aripiprazole Lauroxil

Aripiprazole Monohydrate

Synonyms, international and chemical names:

Aripiprasol

Aripiprasole

Aripipratsoli

Aripiprazol

Aripiprazolo

Aripiprazolum

Arypiprazol

Brands, generics, trade names:

Abilify - Bristol-Myers Squibb, Otsuka Pharmaceutical

Abilify Discmelt - Bristol-Myers Squibb

Abilify Maintena - Bristol-Myers Squibb, Otsuka Pharmaceutical

Abilify Mycite - Bristol-Myers Squibb, Otsuka Pharmaceutical

Aria - Abbott, Intas Pharmaceuticals, Nicholas Piramal, Ranbaxy

Arilex FT - Andromaco Laboratorios

Aripa - Platinum Pharmaceuticals

Aripiprazol - Cinfa Laboratorios, EG Labo, KRKA, Mylan, Pliva, Ratiopharm, Sandoz, Stada, TAD Pharma, Teva

Aripiprazole - Accord Healthcare, Alembic, Apotex, Hetero Drugs, Mylan, Sandoz, Teva, Zentiva, Zydus Pharmaceuticals

Aripiprex - Torrent Pharmaceuticals

Arip-MT - Torrent Pharmaceuticals

Aripra - Ranbaxy

Ariski - Actavis

Aristada - Alkermes

Arpit - Crescent Therapeutics

Arpizol - Sun Pharmaceutical Industries

Arzu - Lupin Pharmaceuticals, Pinnacle CVS

Asprito - Intas Pharmaceuticals

Azymol - Drugtech Laboratorio, Recalcine Laboratorios

Ilimit - Pharma Investi de Chile

Irazem - Roemmers Laboratorios

Pipra-A - Psyco Remedies

Rizotal - Talent Healthcare

Schizopra - Cadila Pharmaceuticals, Cinerea Biotech, Micro Labs

Zolerip - Med Ilac

Here is a list of popular medications containing aripiprazole as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

Trade name of the drug	Pharmaceutical forms and doses	Companies
Abilify	Injectable; Injection; Aripiprazole 7.5 mg / ml Solution; Oral; Aripiprazole 1 mg / ml Tablets, Orally Disintegrating; Oral; Aripiprazole 10 mg Tablets, Orally Disintegrating; Oral; Aripiprazole 15 mg Tablets, Orally Disintegrating; Oral; Aripiprazole 20 mg Tablets, Orally Disintegrating; Oral; Aripiprazole 30 mg Tablets; Oral; Aripiprazole 2 mg Tablets; Oral; Aripiprazole 5 mg Tablets; Oral; Aripiprazole 10 mg Tablets; Oral; Aripiprazole 15 mg Tablets; Oral; Aripiprazole 20 mg Tablets; Oral; Aripiprazole 30 mg	Bristol-Myers Squibb Agencia Lei Va Hong DKSH Otsuka Pharmaceutical Steward Cross Zuellig Pharma
Abilify Discmelt	Tablets, Orally Disintegrating; Oral; Aripiprazole 10 mg Tablets, Orally Disintegrating; Oral; Aripiprazole 15 mg	Bristol-Myers Squibb
Arip-MT	Tablets; Oral; Aripiprazole 2 mg Tablets; Oral; Aripiprazole 5 mg Tablets; Oral; Aripiprazole 10 mg Tablets; Oral; Aripiprazole 15 mg Tablets; Oral; Aripiprazole 20 mg Tablets; Oral; Aripiprazole 30 mg	Torrent Pharmaceuticals
Arpizol	Tablets; Oral; Aripiprazole 5 mg Tablets; Oral; Aripiprazole 10 mg Tablets; Oral; Aripiprazole 15 mg Tablets; Oral; Aripiprazole 20 mg Tablets; Oral; Aripiprazole 30 mg	Sun Pharmaceutical Industries Sin Byu Gyun Trading
Asprito	Tablets; Oral; Aripiprazole 10 mg Tablets; Oral; Aripiprazole 15 mg Tablets; Oral; Aripiprazole 20 mg Tablets; Oral; Aripiprazole 30 mg	Intas Pharmaceuticals

References:

Aripiprazole main article on Wikipedia: https://en.wikipedia.org/wiki/Aripiprazole

Aripiprazole compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Aripiprazole

Aripiprazole on DrugBank: https://go.drugbank.com/drugs/DB01238

Aripiprazole FAQ on MedlinePlus: https://medlineplus.gov/druginfo/meds/a603012.html

Aripiprazole Injection FAQ on MedlinePlus (revised 02/15/2019): https://medlineplus.gov/druginfo/meds/a615048.html

Abilify (Aripiprazole) tablets drug label info on DailyMed (revised August 31, 2010): https://dailymed.nlm.nih.gov/dailymed/drugInfo...

Abilify (Aripiprazole) tablets, oral solution, orally disintegrating tablets, injection solution, drug label info on DailyMed (revised July 8, 2020): https://dailymed.nlm.nih.gov/dailymed/lookup...

Aripiprazole tablets drug label info on DailyMed (revised March 7, 2020): https://dailymed.nlm.nih.gov/dailymed/drugInfo...

Aripiprazole containing drugs on Drugs-About.com: https://drugs-about.com/ing/aripiprazole.html

Aripiprazole for sale on Pharma Doctor: https://pharma-doctor.com/aripiprazole.html

Aripiprazole international drug names on Drugs.com: https://www.drugs.com/international/aripiprazole.html

Abilify and Abilify Discmelt (Aripiprazole) tablets, oral solution, orally disintegrating tablets, injection solution official prescribing information and medication guide from the U.S. FDA (revised 08/2016): https://www.accessdata.fda.gov/drugsatfda_docs/label...

Abilify and Abilify Discmelt (Aripiprazole) tablets, oral solution, orally disintegrating tablets, injection solution prescribing information and medication guide from Otsuka Pharmaceutical company (revised 06/2020): https://www.otsuka-us.com/media/static/Abilify-PI.pdf

Abilify (Aripiprazole) 2, 5, 10, 15, 20, 30 mg tablets official website: https://www.abilify.com/

Abilify (Aripiprazole) 5 mg, 10 mg, 15 mg, 30 mg tablets package information leaflet on Medicines.org.uk (revised 09/2020): https://www.medicines.org.uk/emc/files/pil.7148.pdf

Revised: April 2021